Rosalind Advisors Inc. Purchases 25,000 Shares of Verona Pharma plc (NASDAQ:VRNA)

Rosalind Advisors Inc. lifted its position in shares of Verona Pharma plc (NASDAQ:VRNA - Free Report) by 10.0% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 275,000 shares of the company's stock after purchasing an additional 25,000 shares during the quarter. Verona Pharma makes up about 5.0% of Rosalind Advisors Inc.'s investment portfolio, making the stock its 8th largest position. Rosalind Advisors Inc. owned 0.34% of Verona Pharma worth $7,912,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of VRNA. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Verona Pharma by 25.4% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,610 shares of the company's stock valued at $75,000 after purchasing an additional 529 shares during the last quarter. GAMMA Investing LLC lifted its stake in Verona Pharma by 70.6% in the third quarter. GAMMA Investing LLC now owns 1,336 shares of the company's stock valued at $38,000 after acquiring an additional 553 shares during the last quarter. CWM LLC bought a new position in shares of Verona Pharma during the 2nd quarter worth approximately $29,000. EMC Capital Management bought a new stake in shares of Verona Pharma during the 2nd quarter worth about $38,000. Finally, Sei Investments Co. grew its holdings in Verona Pharma by 3.7% in the 1st quarter. Sei Investments Co. now owns 74,294 shares of the company's stock valued at $1,195,000 after buying an additional 2,640 shares in the last quarter. Institutional investors own 85.88% of the company's stock.

Insider Buying and Selling

In other news, CEO David Zaccardelli sold 46,888 shares of Verona Pharma stock in a transaction dated Friday, November 1st. The stock was sold at an average price of $4.38, for a total transaction of $205,369.44. Following the sale, the chief executive officer now directly owns 15,298,896 shares of the company's stock, valued at approximately $67,009,164.48. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other news, CEO David Zaccardelli sold 46,888 shares of Verona Pharma stock in a transaction on Friday, November 1st. The shares were sold at an average price of $4.38, for a total transaction of $205,369.44. Following the transaction, the chief executive officer now owns 15,298,896 shares in the company, valued at approximately $67,009,164.48. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Mark W. Hahn sold 116,696 shares of the stock in a transaction on Monday, October 21st. The shares were sold at an average price of $4.38, for a total value of $511,128.48. Following the completion of the sale, the chief financial officer now owns 13,973,264 shares of the company's stock, valued at $61,202,896.32. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 1,139,544 shares of company stock worth $4,992,952 in the last 90 days. Insiders own 4.80% of the company's stock.

Analyst Ratings Changes

VRNA has been the topic of a number of recent analyst reports. Wells Fargo & Company raised their price target on Verona Pharma from $50.00 to $64.00 and gave the stock an "overweight" rating in a research report on Tuesday. HC Wainwright raised their target price on shares of Verona Pharma from $36.00 to $42.00 and gave the company a "buy" rating in a report on Tuesday. Truist Financial boosted their target price on shares of Verona Pharma from $38.00 to $44.00 and gave the company a "buy" rating in a research report on Wednesday, October 9th. Finally, Canaccord Genuity Group increased their price target on shares of Verona Pharma from $37.00 to $44.00 and gave the stock a "buy" rating in a research report on Tuesday. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Verona Pharma currently has an average rating of "Buy" and an average price target of $43.83.

Verona Pharma Price Performance

Shares of Verona Pharma stock traded down $0.80 during midday trading on Wednesday, hitting $37.59. 1,019,212 shares of the company traded hands, compared to its average volume of 923,590. The firm's fifty day moving average price is $31.28 and its 200-day moving average price is $22.59. The stock has a market cap of $3.05 billion, a price-to-earnings ratio of -19.58 and a beta of 0.42. Verona Pharma plc has a 12 month low of $11.39 and a 12 month high of $39.40. The company has a debt-to-equity ratio of 0.72, a quick ratio of 8.61 and a current ratio of 8.61.

Verona Pharma (NASDAQ:VRNA - Get Free Report) last posted its earnings results on Monday, November 4th. The company reported ($0.56) earnings per share for the quarter, missing analysts' consensus estimates of ($0.44) by ($0.12). The business had revenue of $5.62 million for the quarter, compared to analysts' expectations of $2.31 million. During the same quarter in the previous year, the firm posted ($0.18) earnings per share. As a group, sell-side analysts forecast that Verona Pharma plc will post -2.07 earnings per share for the current year.

Verona Pharma Profile

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.